Website
News25/Ratings0
News · 26 weeks9-100%
2025-10-262026-04-19
Mix390d
- SEC Filings3(100%)
Latest news
25 items- SECBone Biologics Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Bone Biologics Corp (0001419554) (Filer)
- SECSEC Form 424B5 filed by Bone Biologics Corp424B5 - Bone Biologics Corp (0001419554) (Filer)
- SECSEC Form 10-K filed by Bone Biologics Corp10-K - Bone Biologics Corp (0001419554) (Filer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Walsh Deina H4 - Bone Biologics Corp (0001419554) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Frelick Jeff4 - Bone Biologics Corp (0001419554) (Issuer)
- SECBone Biologics Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Bone Biologics Corp (0001419554) (Filer)
- PRBone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 OutlookBURLINGTON, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW)), a developer of orthobiologic products for spine fusion markets, today summarized key corporate, scientific, and operational milestones achieved during 2025 and outlined its strategic outlook for 2026. "We executed with discipline throughout 2025 as we focused on strengthening the foundation required to advance our clinical program," stated Bone Biologics CEO Jeff Frelick. "During the year, we made meaningful progress across product readiness, intellectual property, and capital structure, including extending the validated shelf life of our rhNELL-1 prot
- PRBone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 MonthsBURLINGTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW)), a developer of orthobiologic products for spine fusion markets, announces it has received confirmation that the shelf life of its rhNELL-1 product has been extended to 24 months, delivering on previously communicated forecasts. The extended shelf life is validated by ongoing stability data and represents a logical progression from prior validated 12- and 18-month shelf-life milestones. Achieving a 24-month shelf life is expected to enhance manufacturing efficiency, inventory management, supply-chain flexibility, and clinical and commercial readiness as
- SECSEC Form 10-Q filed by Bone Biologics Corp10-Q - Bone Biologics Corp (0001419554) (Filer)
- SECSEC Form S-8 filed by Bone Biologics CorpS-8 - Bone Biologics Corp (0001419554) (Filer)
- SECBone Biologics Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Bone Biologics Corp (0001419554) (Filer)
- PRBone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and OutlookBone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW)), a developer of orthobiologic products for spine fusion markets, announces that President and Chief Executive Officer Jeffrey Frelick has issued the following letter to stockholders. To My Fellow Stockholders: I am pleased to provide a progress report on Bone Biologics' development of NB1 and to review our expected milestones for the coming year, including the anticipated completion of enrollment in our first-in-human study and an interim update. As a reminder, NB1 consists of the recombinant human protein NELL-1 (rhNELL-1) combined with demineralized bone matrix (DBM). NELL-1 has several unique prope
- PRBone Biologics to Participate in the H.C. Wainwright Global Investment ConferenceBone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW)), a developer of orthobiologic products for spine fusion markets, announces that Jeffrey Frelick, President and Chief Executive Officer, will participate in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025. Management will be available during the conference for in-person and virtual one-on-one meetings. Institutional investors and industry professionals can register to attend the conference virtually or in-person at the Lotte New York Palace Hotel. About Bone Biologics Bone Biologics was founded to pursue regenerative medicine for bone. The Company is underta
- SECSEC Form EFFECT filed by Bone Biologics CorpEFFECT - Bone Biologics Corp (0001419554) (Filer)
- SECAmendment: SEC Form S-3/A filed by Bone Biologics CorpS-3/A - Bone Biologics Corp (0001419554) (Filer)
- SECSEC Form 10-Q filed by Bone Biologics Corp10-Q - Bone Biologics Corp (0001419554) (Filer)
- SECSEC Form 8-K filed by Bone Biologics Corp8-K - Bone Biologics Corp (0001419554) (Filer)
- PRBone Biologics Announces Closing of $5.0 Million Public OfferingBone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW)), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced public offering of an aggregate of 1,250,000 shares of its common stock (or common stock equivalents in lieu thereof), Series D warrants to purchase up to 1,250,000 shares of common stock and Series E short-term warrants to purchase up to 1,250,000 shares of common stock, at a public offering price of $4.00 per share (or common stock equivalent in lieu thereof) and accompanying warrants. The Series D warrants have an exercise price of $4.00 per share, are exercisable immediately upon issu
- SECSEC Form 424B4 filed by Bone Biologics Corp424B4 - Bone Biologics Corp (0001419554) (Filer)
- SECSEC Form EFFECT filed by Bone Biologics CorpEFFECT - Bone Biologics Corp (0001419554) (Filer)
- PRBone Biologics Announces Pricing of $5.0 Million Public OfferingBone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW)), a developer of orthobiologic products for spine fusion markets, today announced the pricing of its public offering of an aggregate of 1,250,000 shares of its common stock (or common stock equivalents in lieu thereof), Series D warrants to purchase up to 1,250,000 shares of common stock and Series E short-term warrants to purchase up to 1,250,000 shares of common stock, at a public offering price of $4.00 per share (or common stock equivalent in lieu thereof) and accompanying warrants. The Series D warrants will have an exercise price of $4.00 per share, will be exercisable immediately upon issuance and wil
- PRBone Biologics Files Patent Application for Bone Regeneration TechnologyBone Biologics Corporation ("Bone Biologics" or the "Company) (NASDAQ:BBLG, BBLGW)), a developer of orthobiologic products for spine fusion markets, announces the filing of a patent application with the United States Patent and Trademark Office (USPTO) for its novel NELL-1 protein. The patent application is directed to compositions of rhNELL-1 polypeptide and uses thereof for treating bone conditions. "This patent application marks a major milestone in our mission to bring effective treatments to spine fusion patients," said Jeffrey Frelick, Chief Executive Officer of Bone Biologics. The patent application, if approved, will strengthen Bone Biologics' intellectual property portfolio a
- SECSEC Form 8-K filed by Bone Biologics Corp8-K - Bone Biologics Corp (0001419554) (Filer)
- PRBone Biologics Regains Compliance with Nasdaq Continued Listing RequirementsBone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW)), a developer of orthobiologic products for spine fusion markets, today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule") for continued listing on the Nasdaq Capital Market. Bone Biologics is now in compliance with all applicable listing standards and its common stock will continue to be listed on the Nasdaq Capital Market. Bone Biologics was notified by Nasdaq on April 7, 2025 that it was not in compliance with the Rule because its c
- SECSEC Form S-3 filed by Bone Biologics CorpS-3 - Bone Biologics Corp (0001419554) (Filer)